江西同和药业股份有限公司投资者关系活动记录表 | 证券简称:同和药业 | 证券代码:300636 编号:2023007 | | --- | --- | | | □特定对象调研 □分析师会议 | | | □媒体采访 业绩说明会 | | 投资者关系活动类型 | □新闻发布会 □路演活动 | | | □现场参观 □其他( ) | | 参与单位名称及人员姓名 | 通过深交所互动易平台（http://irm.cninfo.com.cn）"云 | | | 访谈"参与同和药业2022年度网上业绩说明会的投资者。 | | 时间 | 2023年5月17日15:00-16:00 | | 地点 | 公司会议室 | | 公司接待人员姓名 | 公司董事长、总经理庞正伟先生，独立董事彭昕先生，副 | | | 总经理兼董事会秘书周志承先生，财务负责人胡锦桥先生， | | | 保荐代表人刘海燕女士。 1、问：请问公司二厂区建设进度如何？ | | | 答：二厂区一期工程4个车间均已处于试生产阶段。二厂区 一期装置完成试生产后，将使替格瑞洛、维格列汀、阿齐 | | | 沙坦、米拉贝隆、阿哌沙班、依度沙班、富马酸伏诺拉生、 | | | 阿戈美拉 ...

证券代码：300636 证券简称：同和药业 公告编号：2023-034 江西同和药业股份有限公司 关于参加江西辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，江西同和药业股份有限公司 （以下简称"公司"）将参加由江西证监局、江西省上市公司协会与 深圳市全景网络有限公司联合举办的 "2023年江西辖区上市公司投 资者集体接待日活动",现将相关事项公告如下: 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站(https://rs.p5w.net)，或关注微信公众号：全景财经，或下载 全景路演APP，参与本次互动交流，活动时间为2023年5月19日（周五） 15:30-17:00。届时公司高管将在线就公司2022年度业绩、公司治理、 发展战略、经营状况、融资计划、股权激励和可持续发展等投资者关 心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 江西同和药业股份有限公司董事会 二〇二三年五月十五日 1/ 1 ...

证券代码：300636 证券简称：同和药业 公告编号：2023-032 江西同和药业股份有限公司 关于举行 2022 年度网上业绩说明会的公告 江西同和药业股份有限公司（以下简称"公司"）已于2023年4 月24日在巨潮资讯网（www.cninfo.com.cn）上披露了《2022年年度 报告》。 为使投资者更全面地了解公司2022年年度报告的内容，公司定于 2023年5月17日（星期三）下午15:00-16:00举行2022年度网上业绩说 明会，本次年度业绩说明会将通过深圳证券交易所提供的"互动易" 平台举行，投资者可登录"互动易"网站（http://irm.cninfo.com.cn） 进入"云访谈"栏目参与本次年度业绩说明会。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特此公告。 江西同和药业股份有限公司董事会 二〇二三年五月九日 1/ 1 出席本次年度业绩说明会的人员有：公司董事长、总经理庞正伟 先生，独立董事彭昕先生，副总经理兼董事会秘书周志承先生，财务 负责人胡锦桥先生，保荐代表人刘海燕女士等。 为充分尊重投资者、提升交流的针对性，现就公司2 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 220,746,478.69, representing a 22.79% increase compared to CNY 179,771,415.86 in the same period last year[5] - Net profit attributable to shareholders was CNY 33,096,474.74, up 23.36% from CNY 26,828,215.64 year-on-year[5] - The total operating revenue for the first quarter of 2023 was CNY 220,746,478.69, an increase of 22.8% compared to CNY 179,771,415.86 in the same period last year[23] - The net profit attributable to the parent company for the first quarter of 2023 was CNY 33,096,474.74, compared to CNY 26,828,215.64 in the previous year, representing a growth of 23.4%[24] - The total comprehensive income for the first quarter of 2023 was CNY 33,096,474.74, an increase from CNY 26,828,215.64 in the same period last year, representing a growth of approximately 23.5%[25] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 11.59% to CNY 85,264,632.48 from CNY 96,438,592.52 in the previous year[10] - The company's cash and cash equivalents decreased by 40.15% to CNY 84,960,709.82 from CNY 141,963,915.05 at the beginning of the period[7] - The net cash flow from financing activities increased significantly by 260.43% to CNY 79,153,361.13 from a negative CNY 49,338,103.33 in the previous year[11] - Net cash flow from operating activities was CNY 85,264,632.48, down from CNY 96,438,592.52 in the previous year, indicating a decrease of approximately 11.1%[28] - The company reported a decrease in cash and cash equivalents by CNY 47,370,255.23, compared to a decrease of CNY 81,640,864.77 in the previous year[28] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,333,114,239.79, a 3.29% increase from CNY 2,258,855,478.13 at the end of the previous year[5] - The total liabilities increased to CNY 972,001,271.81 from CNY 939,186,880.03, indicating a rise of 3.5%[22] - Accounts receivable increased to CNY 117,611,560.19 from CNY 87,829,525.65, marking a growth of 33.9%[21] - Inventory decreased to CNY 467,125,058.50 from CNY 497,358,472.51, a reduction of 6.1%[21] Research and Development - Research and development expenses increased by 67.09% to CNY 19,210,151.13 compared to CNY 11,496,727.71 in the same period last year[9] - The company's R&D expenses for the first quarter of 2023 were CNY 19,210,151.13, up from CNY 11,496,727.71, reflecting a significant increase of 67.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,625[13] - The largest shareholder, Mr. Pang Zhengwei, holds 18.85% of shares, totaling 66,009,954 shares, with 15,750,000 shares pledged[13] - The second largest shareholder, Fenglong Industrial Co., Ltd., holds 15.85% of shares, totaling 55,511,352 shares[13] - The company’s major shareholders, including Mr. Pang and Mr. Liang, are considered acting in concert, jointly controlling the company[14] Capital Projects and Investments - The company has completed the first phase of its new plant project, which includes four workshops that are now in trial production[17] - The company is expanding its second plant with new construction and renovation projects, which commenced in July 2022[17] - The company has completed the application for a specific issuance of A-shares, which has been approved by the Shenzhen Stock Exchange and the China Securities Regulatory Commission[18] Stock and Incentives - The total number of restricted shares at the beginning of the period was 60,606,349, with 77,813 shares released during the period[16] - The company has a stock incentive plan with a total of 5,362,650 shares subject to restrictions[16] - The company has a total of 8,800,000 shares held by Guotai Junan's flexible allocation mixed fund[14] - The company has a total of 3,000,000 shares held by Agricultural Bank of China’s innovative growth mixed fund[14] Operating Costs - The total operating costs for the first quarter of 2023 were CNY 178,963,287.50, up from CNY 149,238,774.57, reflecting a year-over-year increase of 19.9%[24] - The cash inflow from sales of goods and services was CNY 176,923,633.02, slightly down from CNY 176,974,887.71 in the previous year, showing a marginal decline of about 0.03%[28] - The total cash outflow from operating activities was CNY 107,476,010.99, which increased from CNY 102,135,796.85 in the previous year, indicating a rise of approximately 5.3%[28] Other Information - The company did not report any new product launches or technological advancements during this quarter[29]

Financial Performance - The company's operating revenue for 2022 was CNY 719,908,426.87, representing a 21.58% increase compared to CNY 592,126,648.93 in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 100,667,359.97, up 24.10% from CNY 81,119,813.17 in 2021[24]. - The cash flow from operating activities increased by 49.23% to CNY 195,996,737.04 in 2022, compared to CNY 131,338,816.17 in 2021[24]. - The total assets at the end of 2022 reached CNY 2,258,855,478.13, an 18.47% increase from CNY 1,906,727,705.65 at the end of 2021[24]. - The net assets attributable to shareholders increased by 48.59% to CNY 1,319,668,598.10 at the end of 2022, compared to CNY 888,112,993.37 at the end of 2021[24]. - The basic earnings per share for 2022 were CNY 0.3084, a 17.40% increase from CNY 0.2627 in 2021[24]. - The company reported a total of CNY 3,271,050.26 in non-recurring gains and losses for 2022, compared to CNY 1,929,871.51 in 2021[30]. - The company achieved a sales revenue of 719.91 million yuan, a year-on-year increase of 21.58%[67]. - The external sales reached 583.91 million yuan, with a growth of 26.79% compared to the previous year[67]. - The net profit for the period was 100.67 million yuan, representing a 24.10% increase from the previous year[67]. - The company reported a total revenue of 1.5 billion for the year 2022, representing a year-on-year growth of 15%[134]. - The company reported a total revenue of 1,644 million in 2022, with a year-on-year increase of 4.823%[159]. - The net profit for the year was 74.21 million, reflecting a growth of 25.04% compared to the previous year[159]. Research and Development - The average R&D investment over the past three years has been 7.74% of sales, indicating a strong focus on innovation and technology development[39]. - The company has established several technology innovation platforms, including the Jiangxi Provincial Engineering Research Center for Specialty Raw Materials, enhancing its R&D capabilities[39]. - The company has completed bioequivalence (BE) for 13 downstream products, including drugs like Venlafaxine and Celecoxib[45]. - The R&D investment amounted to 60.91 million yuan, accounting for 8.46% of the current operating revenue[67]. - The company has a research and development team of over 400 personnel, ensuring efficient selection and rapid market introduction of products with broad market prospects[57]. - The R&D department has successfully filed for 12 new patents, with 8 already granted, indicating a strong focus on innovation[168]. - The company is investing 50 million RMB in new technology to improve production efficiency, targeting a 15% reduction in operational costs[168]. - The company plans to increase R&D investment to improve innovation capabilities and strengthen the CDMO team's capacity for new drug projects[123]. Market Expansion and Strategy - The company is actively pursuing market expansion and new product development to enhance its competitive position in the pharmaceutical sector[4]. - The company has seen a significant increase in demand for its products due to the rising health awareness among the Chinese population[34]. - The company is gradually expanding its contract processing services for original drug manufacturers, in addition to supplying raw materials for generic drug companies[34]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[129]. - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[127]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 300 million CNY earmarked for potential targets[127]. - The company aims to strengthen brand building and contract manufacturing while focusing on the chemical pharmaceutical industry to enhance its market position[111]. - The company plans to enter two new international markets by the end of 2023[137]. Compliance and Risk Management - The company faces risks related to national policies and industry competition due to ongoing healthcare reforms and regulatory changes[3]. - The company has implemented measures to ensure compliance with environmental standards, but increasing costs for waste management are anticipated due to stricter regulations[5]. - The company has not experienced any major safety incidents to date, but acknowledges potential risks associated with handling hazardous materials in production[5]. - The company’s product quality is subject to high standards, and any quality issues could adversely affect its reputation and operational performance[6]. - The company maintains independence from its controlling shareholders in terms of business, assets, personnel, and finance, with a complete and independent operational system[153]. Employee and Management - The total number of employees at the end of the reporting period is 1,280, with 1,256 from the parent company and 24 from major subsidiaries[181]. - The company has implemented an employee stock incentive plan, with a total of 30.72 million shares allocated for this purpose[159]. - The company has a comprehensive compensation policy that includes competitive salaries, benefits, and performance-based bonuses to motivate employees[182]. - The company aims to enhance its training management system and collaborate with external training institutions to develop employees' potential and management talent[184]. - The company has established a performance evaluation system that links assessment results to compensation, promoting a performance-oriented culture[182]. Environmental Commitment - The company has implemented measures to ensure compliance with environmental standards, but increasing costs for waste management are anticipated due to stricter regulations[5]. - The company's wastewater treatment capacity is 1,500 tons/day and air treatment capacity is 30,000 cubic meters/hour at one facility, showcasing its commitment to environmental standards[38]. - The company has a strong production capacity with over 600 reaction vessels and a total volume exceeding 3 million liters, positioning it competitively in the global market[66]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 25% over the next five years[168]. Shareholder Engagement - The company emphasizes the importance of accurate and timely information disclosure, with the chairman as the primary responsible person for information disclosure[150]. - The company has established various channels for investor communication, including dedicated phone lines and email[150]. - The participation rate of investors in the 2022 first extraordinary general meeting was 46.71%[156]. - The company respects and protects the legitimate rights and interests of stakeholders, emphasizing social responsibility and communication[152].

江西同和药业股份有限公司投资者关系活动记录表 证券简称:同和药业 证券代码:300636 编号:2020001 | --- | --- | --- | |------------------------|-------------------------------|-------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动类型 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | 参与单位名称及人员姓名 | | 1、国金证券股份有限公司 王麟（医药研究组组 | | 时间 | 长） 2020 年 6 月 11 | 日 | | 地点 | | 江西同和药业股份有限公司会议室 | | | | 庞正伟（董事长、总经理）、周志承（副总经理、 | | 公司接待人员姓名 | | | | | | 董事会秘书）、张波(证券事务代表） | | 投资者关系互动／主要内 | 1 、问：公司未来产能规划？ | | | 容介绍 | 答：目前一厂区有 | 11 个原料药 ...

Group 1: Export Business - The company has focused on expanding its export business in regulated markets such as the EU, North America, Japan, and South Korea, with export revenue accounting for over 85% of total revenue from 2017 to 2019, reaching 92% in 2019 [1] - The company is also actively exploring emerging markets in South America, Africa, and other regions, maintaining close relationships with new market clients [2] Group 2: Production Capacity - Currently, the first plant has 11 active API workshops, with an additional workshop under renovation, expected to generate sales revenue of 700-800 million [2] - The second plant is designed with 15 synthesis workshops and 2 formulation workshops, planned to be built in three phases, with the first phase expected to be operational in 2021 [2] Group 3: Product Development - The company has strategically planned its product development based on future growth needs, customer demands, and its capabilities, expanding its product categories beyond five major types to include new varieties in anticoagulants, gout treatment, diabetes, dermatitis, and anemia [3] - Currently, there are 26 API products in production and development, covering several global bestsellers, which helps mitigate operational risks associated with single products [3] Group 4: Market Position and Competition - The company has established a competitive position in the market, with core products like Rebaudioside A, Gabapentin, Celecoxib, and Diclofenac holding significant market shares in their respective segments [3] - The company has developed unique expertise in high-purity products, particularly in the Japanese market, which has the highest standards for product purity and quality [3] Group 5: Impact of COVID-19 - The company's operations have been minimally affected by the COVID-19 pandemic, with some impact on logistics and transportation costs [4] Group 6: Shareholder Activity - The major shareholder, Ningbo Jinghui Venture Capital Partnership, reduced its stake to distribute shares among individual partners, selling a total of 3,820,000 shares before the 2019 annual equity distribution plan [4] - From May 25 to June 16, 2020, the shareholder further reduced its stake by 3,027,040 shares, with 28.12% sold through centralized bidding and 71.88% through block trading, primarily to distribute shares among partners and their relatives [5]

Group 1: Shareholder Actions - Major shareholders reduced their holdings through block trades, totaling 859,000 shares, with transaction prices significantly lower than market expectations [2][3] - The block trades occurred on October 28, 29, and November 4, 2020, with prices at 25.54, 24.97, and 24.73, respectively, leading to a perception of low-price selling [2][3] - The purpose of the reduction was to separate partnership shares into individual names, as required by regulations [2] Group 2: Patent Expirations and Product Development - Key patents expiring in the coming years include: - Ticagrelor: US, South Korea, Brazil in July 2021; Europe in May 2021; Japan in August 2025 - Rivaroxaban: Europe in December 2020 and October 2023; South Korea in October 2021 - Dabigatran: US, Brazil in December 2021; Europe, Japan in February 2023 - Mirabegron: US, Brazil in March 2022; Europe, Japan in October 2023 [3] - The company is enhancing production capacity to avoid gaps due to patent expirations and is focusing on domestic sales of raw materials [4] Group 3: Market Position and Future Outlook - The company holds a strong competitive position in the specialty raw materials market, with significant advantages in scale, quality, and market expansion capabilities [5][6] - The global market for the product Ticagrelor reached over 100 tons in 2019, with an expected total of around 550 tons from 2022 to 2024, indicating a promising growth trajectory [6] - The company anticipates a sales revenue of 700-800 million CNY from its first plant at full capacity, with a peak output value expected in 2021-2022 [8] Group 4: Product Performance and Industry Trends - The company is a major supplier of Gabapentin, Rivaroxaban, and Celecoxib, with Rivaroxaban accounting for approximately 50% of the global market consumption [7] - Future sales of Gabapentin and Celecoxib are expected to increase significantly, driven by cost reductions and process optimizations [7] - The company aims to ensure that more products rank among the top three in their respective global segments [7]

江西同和药业股份有限公司投资者关系活动记录表 证券简称:同和药业 证券代码:300636 编号:2021007 | --- | --- | --- | |-------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------| | 投资者关系活动类型 | 特定对象调研 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n 现场参观 □其他 | □分析师会议 \n( ) | | 参与单位名称及人员姓名 | | 周豫 太平洋证券股份有限公司医药行业首席分析师 | | 时间 | 2021 年8月 12 日 | | | 地点 | 公司会议室 | | | | | | | 公司接待人员姓名 | 秘书）、张波(证券事务代表） | 庞正伟（董事长、总经理）、周志承（副总经理 ...

2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 江西同和药业股份有限公司 2022 年第三季度报告 证券代码：300636 证券简称：同和药业 公告编号：2022-102 江西同和药业股份有限公司 3.第三季度报告是否经过审计 □是 否 1 江西同和药业股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 192,299,826.54 | 27.80% | 5 ...